TrialInternational journal of clinical oncology2016

S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).

Yuji Miyamoto et al.PubMed ↗Publisher ↗

No numbers read from the abstract.